Literature DB >> 9519802

Effect of anti-IL-4 and anti-IL-5 antibodies on allergic airway hyperresponsiveness in mice.

H Tanaka1, H Nagai, Y Maeda.   

Abstract

In order to study the role of IL-4 and IL-5 in allergen-induced airway hyperresponsiveness in mice, the effect of the combined administration of anti-IL-4 and anti-IL-5 monoclonal antibodies (mAbs) on IgE response, airway inflammation and airway hyperresponsiveness was studied in sensitized Balb/c mice. Three inhalations of antigen caused an increase in the number of eosinophils in bronchoalveolar lavage fluid and in airway responsiveness to acetylcholine, with a significant elevation in the serum antigen-specific IgE level. Anti-IL-4 mAb inhibited IgE production but did not affect airway eosinophilia or hyperresponsiveness. Moreover, anti-IL-5 mAb inhibited airway eosinophilia but did not affect IgE production or airway hyperresponsiveness. The combined administration of anti-IL4 and anti-IL-5 mAbs, however, inhibited IgE antibody production, airway eosinophilia and hyperresponsiveness. These results suggest that inhibitory action of IL-4 and IL-5 in combination can effectively suppress the onset of antigen-induced airway hyperresponsiveness in mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519802     DOI: 10.1016/s0024-3205(98)00047-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  Promise and pitfalls in animal-based asthma research: building a better mousetrap.

Authors:  David B Corry; Charles G Irvin
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Disruption of antigen-induced airway inflammation and airway hyper-responsiveness in low affinity neurotrophin receptor p75 gene deficient mice.

Authors:  S Tokuoka; Y Takahashi; T Masuda; H Tanaka; S Furukawa; H Nagai
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.

Authors:  Luigino Calzetta; Beatrice Ludovica Ritondo; Maria Gabriella Matera; Francesco Facciolo; Paola Rogliani
Journal:  Br J Pharmacol       Date:  2020-09-17       Impact factor: 8.739

4.  Unique and overlapping gene expression patterns driven by IL-4 and IL-13 in the mouse lung.

Authors:  Christina C Lewis; Bruce Aronow; John Hutton; Joanna Santeliz; Krista Dienger; Nancy Herman; Fred D Finkelman; Marsha Wills-Karp
Journal:  J Allergy Clin Immunol       Date:  2009-02-26       Impact factor: 10.793

5.  Asthma and therapeutics: recombinant therapies in asthma.

Authors:  Donald W Cockcroft
Journal:  Allergy Asthma Clin Immunol       Date:  2005-03-15       Impact factor: 3.406

6.  Fisetin-treatment alleviates airway inflammation through inhbition of MyD88/NF-κB signaling pathway.

Authors:  Wei Huang; Ming-Li Li; Ming-Yue Xia; Jian-Ying Shao
Journal:  Int J Mol Med       Date:  2018-03-22       Impact factor: 4.101

7.  Local and systemic immunological parameters associated with remission of asthma symptoms in children.

Authors:  Susan Waserman; Parameswaran Nair; Denis Snider; Mary Conway; Lata Jayaram; Lynn M McCleary; Jerry Dolovich; Frederick E Hargreave; Jean S Marshall
Journal:  Allergy Asthma Clin Immunol       Date:  2012-10-08       Impact factor: 3.406

8.  Loki zupa (Luooukezupa) decoction reduced airway inflammation in an OVA-induced asthma mouse model.

Authors:  Ying Wei; Muhammadjan Abduwaki; Mihui Li; Qingli Luo; Jing Sun; Yubao Lv; Mammat Nurahmat; Jingcheng Dong
Journal:  Chin Med       Date:  2016-04-29       Impact factor: 5.455

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.